Pregnant women who are at least 20 weeks pregnant and contract chickenpox are typically treated with oral acyclovir if they seek medical attention within 24 hours of developing the rash. Women who were not born and raised in the UK are at a higher risk of contracting chickenpox when they move to the country. The RCOG recommends prescribing oral acyclovir to pregnant women with chickenpox who are at least 20 weeks pregnant and have developed the rash within 24 hours. acyclovir may also be considered for women who are less than 20 weeks pregnant. If a woman contracts chickenpox before 28 weeks of pregnancy, she should be referred to a fetal medicine specialist five weeks after the infection. The chickenpox vaccine cannot be administered during pregnancy, and VZIG is not effective once the rash has developed. In cases where there is clear clinical evidence of chickenpox infection, antibody testing is unnecessary. Pregnant women with chickenpox should be monitored daily, and if they exhibit signs of severe or complicated chickenpox, they should be referred to a specialist immediately. Adults with chickenpox are at a higher risk of complications such as pneumonia, hepatitis, and encephalitis, and in rare cases, death, so proper assessment and management are crucial.

Chickenpox exposure in pregnancy can pose risks to both the mother and fetus, including fetal varicella syndrome. Post-exposure prophylaxis (PEP) with varicella-zoster immunoglobulin (VZIG) or antivirals should be given to non-immune pregnant women, with timing dependent on gestational age. If a pregnant woman develops chickenpox, specialist advice should be sought and oral acyclovir may be given if she is ≥ 20 weeks and presents within 24 hours of onset of the rash.

If a woman with placenta praevia goes into labour, an emergency caesarean section should be performed regardless of whether there is bleeding or not. Placenta praevia is when the placenta is located partially or fully in the lower uterine segment, and it is more common in multiple and multiparous pregnancies. Sometimes it is detected incidentally during routine antenatal scanning, while in other cases, it may present with symptoms such as vaginal bleeding and haemodynamic shock. If placenta praevia is detected on routine imaging, an elective caesarean section should be considered at 37-38 weeks, especially for grade III and IV placenta praevia, due to the higher risk of postpartum haemorrhage. However, in this scenario, the patient has gone into labour spontaneously, and immediate action is necessary. Therefore, an emergency caesarean section is the correct course of action. Anti-D is recommended for pregnant women with negative rhesus status to prevent antibody production to foetal blood cells. Although the mother’s rhesus status is not given, anti-D is a sensible option when in doubt. Inducing labour with oxytocin is not recommended for patients with placenta praevia as it can stimulate vaginal delivery and increase the risk of postpartum haemorrhage. Discharging the patient to continue the pregnancy as normal is not advisable due to the serious risks involved. Tocolytics, such as nifedipine, are not routinely indicated for patients with placenta praevia in labour, and an emergency caesarean section should take priority.

Management and Prognosis of Placenta Praevia

Placenta praevia is a condition where the placenta is located wholly or partially in the lower uterine segment. If a low-lying placenta is detected at the 20-week scan, a rescan is recommended at 32 weeks. There is no need to limit activity or intercourse unless there is bleeding. If the placenta is still present at 32 weeks and is grade I/II, then a scan every two weeks is recommended. A final ultrasound at 36-37 weeks is necessary to determine the method of delivery. For grades III/IV, an elective caesarean section is recommended between 37-38 weeks. However, if the placenta is grade I, a trial of vaginal delivery may be offered. If a woman with known placenta praevia goes into labour before the elective caesarean section, an emergency caesarean section should be performed due to the risk of post-partum haemorrhage.

In cases where placenta praevia is accompanied by bleeding, the woman should be admitted and an ABC approach should be taken to stabilise her. If stabilisation is not possible, an emergency caesarean section should be performed. If the woman is in labour or has reached term, an emergency caesarean section is also necessary.

The prognosis for placenta praevia has improved significantly, and death is now extremely rare. The major cause of death in women with placenta praevia is post-partum haemorrhage.

Breast Conditions in Lactating Women

Lactating women may experience various breast conditions, including mastitis, breast abscess, cellulitis, engorged breasts, and full breasts.

Mastitis is typically caused by a blocked duct or ascending infection from nipple trauma during breastfeeding. Symptoms include unilateral pain, breast engorgement, and erythema. Treatment involves analgesia, reassurance, and continuing breastfeeding. Antibiotics may be necessary if symptoms persist or a milk culture is positive.

Breast abscess presents as a painful lump in the breast tissue, often with systemic symptoms such as fever and malaise. Immediate treatment is necessary to prevent septicaemia.

Cellulitis is an acute bacterial infection of the breast skin, presenting with erythema, tenderness, swelling, and blister formation. Non-specific symptoms such as rigors, fevers, and malaise may also occur.

Engorged breasts can be primary or secondary, causing bilateral breast pain and engorgement. The skin may appear shiny, and the nipple may appear flat due to stretching.

Full breasts are associated with lactation and cause warm, heavy, and hard breasts. This condition typically occurs between the 2nd and 6th day postpartum.

Treatment for Severe Pre-eclampsia and Eclampsia

The recommended treatment for severe pre-eclampsia or eclampsia is intravenous magnesium sulphate. In addition, antihypertensive treatment is also important, with labetalol being the first line of treatment for hypertension during pregnancy. Nifedipine and methyldopa also have a role to play.

Magnesium sulphate should be administered to patients with severe hypertension and proteinuria, as well as those with mild or moderate hypertension and proteinuria who exhibit symptoms such as severe headache, problems with vision, severe pain just below the ribs or vomiting, papilloedema, signs of clonus, liver tenderness, HELLP syndrome, platelet count falling to below 100 ×109/L, or abnormal liver enzymes.

The administration of magnesium sulphate involves a 4 g loading dose given intravenously over five minutes, followed by an infusion of 1 g/hr for 24 hours. In the event of recurrent seizures, an additional bolus dose of 2-4 g should be given over five minutes.

Overall, the treatment for severe pre-eclampsia and eclampsia involves a combination of intravenous magnesium sulphate and antihypertensive medication, with the dosage and administration of magnesium sulphate varying depending on the patient’s symptoms and condition.

The correct result for the quadruple test screening for Edward’s syndrome is ↓ AFP ↓ oestriol ↓ hCG ↔ inhibin A. This test is offered to pregnant women between 15-20 weeks gestation and measures alpha fetoprotein, unconjugated oestriol, hCG, and inhibin A levels. A ‘high chance’ result would require further screening or diagnostic tests to determine if the baby is affected by Edward’s syndrome. The incorrect answers include a result indicating a higher chance of Down’s syndrome (↑ hCG, ↓ PAPP-A, thickened nuchal translucency), neural tube defects (↑AFP ↔ oestriol ↔ hCG ↔ inhibin A), and a higher chance of Down’s syndrome (↓ AFP ↓ oestriol ↑ hCG ↑ inhibin A). It is important to note that the combined test for Down’s syndrome should not be given to women outside of the appropriate gestation bracket.

NICE updated guidelines on antenatal care in 2021, recommending the combined test for screening for Down’s syndrome between 11-13+6 weeks. The test includes nuchal translucency measurement, serum B-HCG, and pregnancy-associated plasma protein A (PAPP-A). The quadruple test is offered between 15-20 weeks for women who book later in pregnancy. Results are interpreted as either a ‘lower chance’ or ‘higher chance’ of chromosomal abnormalities. If a woman receives a ‘higher chance’ result, she may be offered a non-invasive prenatal screening test (NIPT) or a diagnostic test. NIPT analyzes cell-free fetal DNA in the mother’s blood and has high sensitivity and specificity for detecting chromosomal abnormalities. Private companies offer NIPT screening from 10 weeks gestation.

Different Types of Miscarriage: Symptoms and Diagnosis

Miscarriage is the loss of pregnancy before 20 weeks’ gestation. There are several types of miscarriage, each with its own symptoms and diagnosis.

Missed miscarriage is an incidental finding where the patient presents without symptoms, but the ultrasound shows a small gestational sac and no fetal heart rate.

Complete miscarriage is when all products of conception have been passed, and the uterus is empty and contracted.

Incomplete miscarriage is when some, but not all, products of conception have been expelled, and the patient experiences vaginal bleeding with an open or closed os.

Inevitable miscarriage is when the pregnancy will inevitably be lost, and the patient presents with active bleeding, abdominal pain, and an open cervical os.

Threatened miscarriage is when there is an episode of bleeding, but the pregnancy is unaffected, and the patient experiences cyclical abdominal pain and dark red-brown bleeding. The cervical os is closed, and ultrasound confirms the presence of a gestational sac and fetal heart rate.

It is important to seek medical attention if any symptoms of miscarriage occur.

Possible Causes of Hirsutism in Women: A Differential Diagnosis

Hirsutism, the excessive growth of hair in women in a male pattern, can be caused by various underlying conditions. Here are some possible causes and their distinguishing features:

Molar Pregnancy: This condition is characterized by hypertension in the first trimester of pregnancy. Excessive stimulation of ovarian follicles by high levels of gonadotrophins or human chorionic gonadotrophin (hCG) can lead to the formation of multiple theca lutein cysts bilaterally.

Congenital Adrenal Hyperplasia: This disease, which is mostly found in women, can present with gradual onset of hirsutism without virilization. It is caused by a deficiency of 21-hydroxylase and is characterized by an elevated serum concentration of 17-hydroxyprogesterone.

Luteoma of Pregnancy: This benign, solid ovarian tumor develops during pregnancy and disappears after delivery. It may be associated with excess androgen production, leading to hirsutism and virilization.

Adrenal Tumor: Androgen-secreting adrenal tumors can cause rapid onset of severe hirsutism, with or without virilization. Amenorrhea is found in almost half of the patients, and testosterone and dihydrotestosterone sulfate concentrations are elevated.

Polycystic Ovary Syndrome: Women with this condition are at higher risk of developing pre-eclampsia. However, the development of hypertension in the first trimester of pregnancy makes it more likely that there is a molar pregnancy present, with theca lutein cysts seen on ultrasound.

In summary, hirsutism in women can be caused by various conditions, and a differential diagnosis is necessary to determine the underlying cause and appropriate treatment.

Placental abruption is a condition that occurs when the placenta separates from the uterine wall, leading to maternal bleeding into the space between them. Although the exact cause of this condition is unknown, certain factors have been associated with it, including proteinuric hypertension, cocaine use, multiparity, maternal trauma, and increasing maternal age. Placental abruption is not a common occurrence, affecting approximately 1 in 200 pregnancies.

The clinical features of placental abruption include shock that is disproportionate to the visible blood loss, constant pain, a tender and tense uterus, and a normal lie and presentation of the fetus. The fetal heart may be absent or distressed, and there may be coagulation problems. It is important to be aware of other conditions that may present with similar symptoms, such as pre-eclampsia, disseminated intravascular coagulation (DIC), and anuria.

In summary, placental abruption is a serious condition that can have significant consequences for both the mother and the fetus. Understanding the risk factors and symptoms of this condition is important for early detection and appropriate management.

It is important for pregnant individuals with type 1 diabetes to closely monitor their blood glucose levels by testing multiple times throughout the day. This is recommended by NICE NG3.

Gestational diabetes is a common medical disorder affecting around 4% of pregnancies. Risk factors include a high BMI, previous gestational diabetes, and family history of diabetes. Screening is done through an oral glucose tolerance test, and diagnostic thresholds have recently been updated. Management includes self-monitoring of blood glucose, diet and exercise advice, and medication if necessary. For pre-existing diabetes, weight loss and insulin are recommended, and tight glycemic control is important. Targets for self-monitoring include fasting glucose of 5.3 mmol/l and 1-2 hour post-meal glucose levels.

The patient’s immunity to varicella-zoster needs to be determined urgently by testing for varicella-zoster IgG antibodies in the blood, as she has had some exposure to chickenpox and is unsure of her immunity status. If antibodies are detected, she is considered immune and no further action is required, but she should seek medical care immediately if she develops a rash. Varicella-zoster immunoglobulin should only be administered to non-immune patients within 10 days of exposure. It is important to note that if the patient contracts chickenpox during pregnancy, there is a risk of fetal varicella syndrome if infected before 28 weeks’ gestation. Immunisation during pregnancy is not recommended, but the patient can receive the vaccine postpartum if found to be non-immune. It is safe to receive the vaccine while breastfeeding.

Ursodeoxycholic acid is the recommended initial medical treatment for intrahepatic cholestasis of pregnancy. The patient’s symptoms and abnormal liver function tests, along with her pregnancy status, suggest obstetric cholestasis. The Royal College of Obstetricians and Gynaecologists recommends ursodeoxycholic acid to alleviate pruritus and improve liver function in women with obstetric cholestasis. Cetirizine is not effective for pruritic symptoms during pregnancy, while cholestyramine is the preferred treatment for cholestatic pruritus but is not typically used for obstetric cholestasis. Dexamethasone is not the first-line therapy for obstetric cholestasis. Rifampicin may be used as an alternative treatment for pruritus, but caution should be exercised in patients with pre-existing liver disease due to potential hepatotoxicity, and it is not indicated for obstetric cholestasis.

Intrahepatic Cholestasis of Pregnancy: Symptoms and Management

Intrahepatic cholestasis of pregnancy, also known as obstetric cholestasis, is a condition that affects approximately 1% of pregnancies in the UK. It is characterized by intense itching, particularly on the palms, soles, and abdomen, and may also result in clinically detectable jaundice in around 20% of patients. Raised bilirubin levels are seen in over 90% of cases.

The management of intrahepatic cholestasis of pregnancy typically involves induction of labor at 37-38 weeks, although this practice may not be evidence-based. Ursodeoxycholic acid is also widely used, although the evidence base for its effectiveness is not clear. Additionally, vitamin K supplementation may be recommended.

It is important to note that the recurrence rate of intrahepatic cholestasis of pregnancy in subsequent pregnancies is high, ranging from 45-90%. Therefore, close monitoring and management are necessary for women who have experienced this condition in the past.

The macrocytic anaemia revealed by the full blood count is indicative of a megaloblastic anaemia, as per the blood films. This type of anaemia can be caused by a deficiency in folate or B12. Given that folic acid deficiency is prevalent during pregnancy, it is the most probable cause in this instance. Additionally, the likelihood of coeliac disease exacerbating malabsorption further supports this conclusion.

Folic Acid: Importance, Deficiency, and Prevention

Folic acid is a vital nutrient that is converted to tetrahydrofolate (THF) in the body. It is found in green, leafy vegetables and plays a crucial role in the transfer of 1-carbon units to essential substrates involved in the synthesis of DNA and RNA. However, certain factors such as phenytoin, methotrexate, pregnancy, and alcohol excess can cause a deficiency in folic acid. This deficiency can lead to macrocytic, megaloblastic anemia and neural tube defects.

To prevent neural tube defects during pregnancy, it is recommended that all women take 400mcg of folic acid until the 12th week of pregnancy. Women at higher risk of conceiving a child with a neural tube defect should take 5mg of folic acid from before conception until the 12th week of pregnancy. Women are considered higher risk if they or their partner has a neural tube defect, they have had a previous pregnancy affected by a neural tube defect, or they have a family history of a neural tube defect. Additionally, women with certain medical conditions such as coeliac disease, diabetes, or thalassaemia trait, or those taking antiepileptic drugs, or who are obese (BMI of 30 kg/m2 or more) are also considered higher risk.

In summary, folic acid is an essential nutrient that plays a crucial role in DNA and RNA synthesis. Deficiency in folic acid can lead to serious health consequences, including neural tube defects. However, taking folic acid supplements during pregnancy can prevent these defects and ensure a healthy pregnancy.

If an ectopic pregnancy is larger than 35mm or has a serum B-hCG level exceeding 5,000 IU/L, surgical intervention is necessary. The patient in this scenario is experiencing symptoms such as pain and dizziness, and her tachycardia indicates a risk of instability. While she is currently stable, surgical management should be performed promptly. A laparotomy is not immediately necessary, but the procedure should be carried out as soon as possible. Waiting for a blood hCG is unnecessary, and medical management is not appropriate.

Ectopic pregnancy is a serious condition that requires prompt investigation and management. Women who are stable are typically investigated and managed in an early pregnancy assessment unit, while those who are unstable should be referred to the emergency department. The investigation of choice for ectopic pregnancy is a transvaginal ultrasound, which will confirm the presence of a positive pregnancy test.

There are three ways to manage ectopic pregnancies: expectant management, medical management, and surgical management. The choice of management will depend on various criteria, such as the size of the ectopic pregnancy, whether it is ruptured or not, and the patient’s symptoms and hCG levels. Expectant management involves closely monitoring the patient over 48 hours, while medical management involves giving the patient methotrexate and requires follow-up. Surgical management can involve salpingectomy or salpingostomy, depending on the patient’s risk factors for infertility.

Salpingectomy is the first-line treatment for women without other risk factors for infertility, while salpingostomy should be considered for women with contralateral tube damage. However, around 1 in 5 women who undergo a salpingostomy require further treatment, such as methotrexate and/or a salpingectomy. It is important to carefully consider the patient’s individual circumstances and make a decision that will provide the best possible outcome.

The symptoms described in this question are indicative of a molar pregnancy. To answer this question correctly, a basic understanding of physiology is necessary. Molar pregnancies are characterized by abnormally high levels of beta hCG for the stage of pregnancy, which serves as a tumor marker for gestational trophoblastic disease. Beta hCG has a similar biochemical structure to luteinizing hormone (LH), follicle-stimulating hormone (FSH), and thyroid-stimulating hormone (TSH). Consequently, elevated levels of beta hCG can stimulate the thyroid gland to produce thyroxine (T4) and triiodothyronine (T3), leading to symptoms of thyrotoxicosis. High levels of T4 and T3 negatively impact the pituitary gland, reducing TSH levels overall.
Sources:
Best Practice- Molar Pregnancy
Medscape- Hydatidiform Mole Workup

Gestational trophoblastic disorders refer to a range of conditions that originate from the placental trophoblast. These disorders include complete hydatidiform mole, partial hydatidiform mole, and choriocarcinoma. Complete hydatidiform mole is a benign tumor of trophoblastic material that occurs when an empty egg is fertilized by a single sperm that duplicates its own DNA, resulting in all 46 chromosomes being of paternal origin. Symptoms of this disorder include bleeding in the first or early second trimester, exaggerated pregnancy symptoms, a uterus that is large for dates, and very high levels of human chorionic gonadotropin (hCG) in the serum. Hypertension and hyperthyroidism may also be present. Urgent referral to a specialist center is necessary, and evacuation of the uterus is performed. Effective contraception is recommended to avoid pregnancy in the next 12 months, as around 2-3% of cases may develop choriocarcinoma.

Partial hydatidiform mole, on the other hand, occurs when a normal haploid egg is fertilized by two sperms or by one sperm with duplication of the paternal chromosomes. As a result, the DNA is both maternal and paternal in origin, and the fetus may have triploid chromosomes, such as 69 XXX or 69 XXY. Fetal parts may also be visible. It is important to note that hCG can mimic thyroid-stimulating hormone (TSH), which may lead to hyperthyroidism.

In summary, gestational trophoblastic disorders are a group of conditions that arise from the placental trophoblast. Complete hydatidiform mole and partial hydatidiform mole are two types of these disorders. While complete hydatidiform mole is a benign tumor of trophoblastic material that occurs when an empty egg is fertilized by a single sperm that duplicates its own DNA, partial hydatidiform mole occurs when a normal haploid egg is fertilized by two sperms or by one sperm with duplication of the paternal chromosomes. It is important to seek urgent medical attention and effective contraception to avoid pregnancy in the next 12 months.

The expected fundal height growth per week after 24 weeks is 1 cm, not 2 cm. If the fundal height is increasing by 2 cm per week, there may be a multiple pregnancy or the baby may be larger than expected, requiring further investigation. The fundus should be palpable at the umbilicus by 20 weeks and at the xiphoid sternum by 36 weeks. The head is typically free on palpation until around 37 weeks for nulliparous women, but may engage earlier in multiparous women. Breech presentation is common before 34 weeks and only becomes a concern if preterm labor occurs.

NICE guidelines recommend 10 antenatal visits for first pregnancies and 7 for subsequent pregnancies if uncomplicated. The purpose of each visit is outlined, including booking visits, scans, screening for Down’s syndrome, routine care for blood pressure and urine, and discussions about labour and birth plans. Rhesus negative women are offered anti-D prophylaxis at 28 and 34 weeks. The guidelines also recommend discussing options for prolonged pregnancy at 41 weeks.

After giving birth, women who had gestational diabetes and received medical treatment for it should have their medication stopped. Before leaving the hospital, a plasma glucose test should be done to check for persistent high blood sugar levels. Within 6-13 weeks after delivery, a fasting plasma glucose test should be performed by the GP to determine the risk of developing type 2 diabetes. Depending on the results, women may be advised on lifestyle changes or require further testing. It is important for women who had gestational diabetes to maintain healthy habits and have regular fasting blood glucose tests, as they are at an increased risk of developing type 2 diabetes. In future pregnancies, women with risk factors or a personal history of gestational diabetes should have a 2-hour oral glucose tolerance test at 24-28 weeks. In the postnatal period, a 2-hour glucose tolerance test should only be done if fasting glucose levels are abnormal.

If the fasting glucose level is equal to or greater than 7 mmol/l at the time of gestational diabetes diagnosis, immediate administration of insulin (with or without metformin) is necessary. For patients with a fasting plasma glucose level below 7.0 mmol/L, a trial of diet and exercise with follow-up in 1-2 weeks is appropriate. Within a week of diagnosis, the patient should be seen in a joint antenatal and diabetic clinic. Statins are not recommended during pregnancy due to potential congenital abnormalities resulting from reduced cholesterol synthesis. Sitagliptin, a DPP-4 inhibitor, is also not recommended for use during pregnancy or breastfeeding.

Gestational diabetes is a common medical disorder affecting around 4% of pregnancies. Risk factors include a high BMI, previous gestational diabetes, and family history of diabetes. Screening is done through an oral glucose tolerance test, and diagnostic thresholds have recently been updated. Management includes self-monitoring of blood glucose, diet and exercise advice, and medication if necessary. For pre-existing diabetes, weight loss and insulin are recommended, and tight glycemic control is important. Targets for self-monitoring include fasting glucose of 5.3 mmol/l and 1-2 hour post-meal glucose levels.

Understanding Down Syndrome Screening Tests

Down syndrome screening tests are important for pregnant women to determine the likelihood of their baby having the condition. One of the most common tests is the combined test, which is performed between 11+0 and 13+6 weeks’ gestation. This test involves a blood test and an ultrasound scan to measure serum pregnancy-associated plasma protein A (PAPP-A) and β-hCG, as well as nuchal translucency. The results are combined to give an individual risk of having a baby with Down syndrome.

If a woman misses the window for the combined test, she can opt for the quadruple test, which is performed between weeks 15 and 16 of gestation. This test measures four serum markers: inhibin, aFP, unconjugated oestriol, and total serum hCG. Low aFP and unconjugated oestriol, as well as raised inhibin and hCG, are associated with Down syndrome.

It is important to note that these tests are not diagnostic, but rather provide a risk assessment. Women who are classified as high risk may opt for a diagnostic test, such as amniocentesis or chorionic villous sampling, to confirm the presence of an extra chromosome. All pregnant women in the UK should be offered Down syndrome screening and given the opportunity to make an informed decision about participating in the test.

Vasa praevia is a complication where the blood vessels of the fetus are located near or cross the internal opening of the uterus. If the supporting membranes rupture, the vessels can easily be damaged, resulting in bleeding. The classic symptoms of vasa praevia include painless vaginal bleeding and fetal bradycardia following the rupture of membranes. While there is no significant risk to the mother, fetal mortality rates are high. It can be challenging to differentiate vasa praevia from placenta praevia in emergency situations, but a preceding rupture of membranes is usually highlighted in exams. Although ultrasound scans can identify vasa praevia, some cases may go undetected during pregnancy.

Understanding Bleeding During Pregnancy

Bleeding during pregnancy can be a cause for concern and should be promptly evaluated by a healthcare professional. There are various causes of bleeding during pregnancy, which can be categorized based on the trimester in which they occur. In the first trimester, the major causes of bleeding include spontaneous abortion, ectopic pregnancy, and hydatidiform mole. In the second trimester, bleeding may be due to spontaneous abortion, hydatidiform mole, or placental abruption. In the third trimester, bleeding may be caused by placental abruption, placenta praevia, or vasa praevia.

It is important to note that conditions such as sexually transmitted infections and cervical polyps should also be ruled out as potential causes of bleeding during pregnancy. Each condition has its own unique features that can help in diagnosis. For instance, spontaneous abortion may present as threatened miscarriage, missed miscarriage, or inevitable miscarriage, depending on the extent of fetal and placental tissue expulsion. Ectopic pregnancy is typically characterized by lower abdominal pain and vaginal bleeding, while hydatidiform mole may present with exaggerated pregnancy symptoms and high serum hCG levels.

Placental abruption is usually accompanied by constant lower abdominal pain and a tender, tense uterus, while placenta praevia may present with painless vaginal bleeding and an abnormal lie and presentation. Vasa praevia is characterized by rupture of membranes followed immediately by vaginal bleeding and fetal bradycardia.

Understanding the Signs of a Good Latch for Successful Breastfeeding

Latching on the breast is crucial for successful breastfeeding, but many women struggle with it. A poor latch can lead to pain and frustration, causing some women to give up on breastfeeding altogether. However, there are clear signs of a good latch that can help mothers and babies achieve successful breastfeeding.

One indicator of a poor latch is clicking noises, which can be painful for the mother and indicate that the baby is chewing on the nipple. In contrast, a good latch is associated with visible and audible swallowing, a rhythmic suck, and relaxed arms and hands of the infant. The baby’s chin should touch the breast, with the nose free, and the lips should be rolled out, not turned in. The mouth should be open wide, and the tongue positioned below the nipple, with the latter touching the palate of the baby’s mouth.

Another sign of a good latch is that less areola should be visible below the chin than above the nipple. This indicates that the baby is taking in not only the nipple but also the areola, which is essential for effective milk expression and feeding. By understanding these signs of a good latch, mothers can ensure successful breastfeeding and a positive experience for both themselves and their babies.

Lactation mastitis is a prevalent inflammatory condition of the breast that can have infectious or non-infectious origins. The primary cause is milk stasis, which can occur due to either overproduction or insufficient removal.

In cases of non-infectious mastitis, the accumulation of milk leads to an inflammatory response. Occasionally, an infection may develop through retrograde spread via a lactiferous duct or a traumatised nipple, with Staphylococcus aureus being the most common organism.

Symptoms of lactation mastitis include breast pain (usually unilateral) accompanied by an erythematosus, warm, and tender area. Patients may also experience fever and flu-like symptoms.

The first-line approach to managing lactation mastitis is conservative, involving analgesia and encouraging effective milk removal (either through continued breastfeeding or expressing from the affected side) to prevent further milk stasis. It is also crucial to ensure proper positioning and attachment during feeding.

If symptoms do not improve after 12-24 hours of conservative management, antibiotics should be prescribed. The first-line choice is oral flucloxacillin (500 mg four times a day for 14 days), or erythromycin if the patient is allergic to penicillin. Co-amoxiclav is the second-line choice.

In cases where conservative and antibiotic management do not improve symptoms, other more serious causes, such as inflammatory breast cancer, should be considered. (Source – CKS mastitis)

Breastfeeding Problems and Their Management

Breastfeeding is a natural process, but it can come with its own set of challenges. Some of the minor problems that breastfeeding mothers may encounter include frequent feeding, nipple pain, blocked ducts, and nipple candidiasis. These issues can be managed by seeking advice on proper positioning, trying breast massage, and using appropriate medication.

Mastitis is a more serious problem that affects around 1 in 10 breastfeeding women. It is characterized by symptoms such as fever, nipple fissure, and persistent pain. Treatment involves the use of antibiotics, such as flucloxacillin, for 10-14 days. Breastfeeding or expressing milk should continue during treatment to prevent complications such as breast abscess.

Breast engorgement is another common problem that causes breast pain in breastfeeding women. It occurs in the first few days after birth and affects both breasts. Hand expression of milk can help relieve the discomfort of engorgement. Raynaud’s disease of the nipple is a less common problem that causes nipple pain and blanching. Treatment involves minimizing exposure to cold, using heat packs, and avoiding caffeine and smoking.

If a breastfed baby loses more than 10% of their birth weight in the first week of life, it may be a sign of poor weight gain. This should prompt consideration of the above breastfeeding problems and an expert review of feeding. Monitoring of weight should continue until weight gain is satisfactory.

If a woman’s Bishop’s score is 8 or higher, it indicates that her cervix is ripe and there is a high likelihood of spontaneous labor or response to labor-inducing interventions. In the case of a woman whose amniotic sac has ruptured but is not yet showing signs of labor, a Bishop’s score can be used to determine the likelihood of spontaneous labor. If her score is 8 or higher, there is no need to intervene and the best course of action is to monitor and reassure her. Inserting a Cook balloon, performing a membrane sweep, or administering an oxytocin infusion would not be appropriate in this situation.

Induction of labour is a process where labour is artificially started and is required in about 20% of pregnancies. It is indicated in cases of prolonged pregnancy, prelabour premature rupture of the membranes, maternal medical problems, diabetic mother over 38 weeks, pre-eclampsia, obstetric cholestasis, and intrauterine fetal death. The Bishop score is used to assess whether induction of labour is necessary and includes cervical position, consistency, effacement, dilation, and fetal station. A score of less than 5 indicates that labour is unlikely to start without induction, while a score of 8 or more indicates a high chance of spontaneous labour or response to interventions made to induce labour.

Possible methods of induction include membrane sweep, vaginal prostaglandin E2, oral prostaglandin E1, maternal oxytocin infusion, amniotomy, and cervical ripening balloon. The NICE guidelines recommend vaginal prostaglandins or oral misoprostol if the Bishop score is less than or equal to 6, while amniotomy and an intravenous oxytocin infusion are recommended if the score is greater than 6.

The main complication of induction of labour is uterine hyperstimulation, which refers to prolonged and frequent uterine contractions that can interrupt blood flow to the intervillous space and result in fetal hypoxemia and acidemia. Uterine rupture is a rare but serious complication. Management includes removing vaginal prostaglandins and stopping the oxytocin infusion if one has been started, and considering tocolysis.

It should be noted that a significant percentage of women who experience threatened miscarriages will ultimately miscarry. Additionally, it is crucial to consider the possibility of an ectopic pregnancy in pregnant patients who present with both pain and bleeding.

Miscarriage is a common complication that can occur in up to 25% of all pregnancies. There are different types of miscarriage, each with its own set of symptoms and characteristics. Threatened miscarriage is painless vaginal bleeding that occurs before 24 weeks, typically at 6-9 weeks. The bleeding is usually less than menstruation, and the cervical os is closed. Missed or delayed miscarriage is when a gestational sac containing a dead fetus is present before 20 weeks, without the symptoms of expulsion. The mother may experience light vaginal bleeding or discharge, and the symptoms of pregnancy may disappear. Pain is not usually a feature, and the cervical os is closed. Inevitable miscarriage is characterized by heavy bleeding with clots and pain, and the cervical os is open. Incomplete miscarriage occurs when not all products of conception have been expelled, and there is pain and vaginal bleeding. The cervical os is open in this type of miscarriage.

The symphysis-fundal height measurement in centimetres should correspond to the foetal gestational age in weeks with an accuracy of 1 or 2 cm from 20 weeks gestation. Hence, it can be deduced that the woman is possibly experiencing fetal growth restriction. Therefore, it is crucial to conduct an ultrasound to verify if the foetus is indeed small for gestational age.

The symphysis-fundal height (SFH) is a measurement taken from the pubic bone to the top of the uterus in centimetres. It is used to determine the gestational age of a fetus and should match within 2 cm after 20 weeks. For example, if a woman is 24 weeks pregnant, a normal SFH would be between 22 and 26 cm. Proper measurement of SFH is important for monitoring fetal growth and development during pregnancy.

If a baby has a birth weight greater than 4kg, regardless of their gestational age, they are diagnosed with foetal macrosomia. This condition can cause dystocia, which may result in injuries to both the mother and baby. Dystocia may also require an operative vaginal delivery or Caesarean-section. Shoulder dystocia is the most common cause of damage to the upper brachial plexus, resulting in Erb’s palsy. This condition is characterized by the arm being adducted and internally rotated, with the forearm pronated, commonly referred to as the ‘waiter’s tip’. Damage to the lower brachial plexus can cause Klumpke’s palsy, which commonly affects the nerves that innervate the muscles of the hand.

Shoulder dystocia is a complication that can occur during vaginal delivery when the body of the fetus cannot be delivered after the head has already been delivered. This is usually due to the anterior shoulder of the fetus becoming stuck on the mother’s pubic bone. Shoulder dystocia can cause harm to both the mother and the fetus. Risk factors for shoulder dystocia include fetal macrosomia, high maternal body mass index, diabetes mellitus, and prolonged labor.

If shoulder dystocia is identified, it is important to call for senior help immediately. The McRoberts’ maneuver is often performed, which involves flexing and abducting the mother’s hips to increase the angle of the pelvis and facilitate delivery. An episiotomy may be performed to provide better access for internal maneuvers, but it will not relieve the bony obstruction. Symphysiotomy and the Zavanelli maneuver are not recommended as they can cause significant maternal morbidity. Oxytocin administration is not indicated for shoulder dystocia.

Complications of shoulder dystocia can include postpartum hemorrhage and perineal tears for the mother, and brachial plexus injury and neonatal death for the fetus. It is important to manage shoulder dystocia promptly and appropriately to minimize the risk of these complications.

Teratogenic Effects of Medications on Fetal Development

Certain medications can have harmful effects on fetal development, leading to birth defects and other medical conditions. Phenytoin and carbamazepine, commonly used to treat seizures, are known to cause fetal hydantoin syndrome, which can result in intrauterine growth restriction, microcephaly, cleft lip/palate, intellectual disability, hypoplastic fingernails, distal limb deformities, and developmental delay. Meningomyelocele, a neural tube defect, can be associated with valproic acid use and folate deficiency. Omphalocele, an abdominal wall defect, is linked to chromosomal abnormalities but not medication use. Congenital diaphragmatic hernia can lead to pulmonary hypoplasia and pulmonary hypertension, but it is not caused by phenytoin use. While phenytoin and carbamazepine are used to treat seizures, they do not typically cause seizures in infants exposed to the drugs in utero. It is important for healthcare providers to carefully consider the potential risks and benefits of medication use during pregnancy to ensure the best possible outcomes for both mother and baby.

If the baby loses more than 10% of his birth weight in the first week, immediate measures must be taken to ensure proper feeding.

Breastfeeding Problems and Their Management

Breastfeeding is a natural process, but it can come with its own set of challenges. Some of the minor problems that breastfeeding mothers may encounter include frequent feeding, nipple pain, blocked ducts, and nipple candidiasis. These issues can be managed by seeking advice on proper positioning, trying breast massage, and using appropriate medication.

Mastitis is a more serious problem that affects around 1 in 10 breastfeeding women. It is characterized by symptoms such as fever, nipple fissure, and persistent pain. Treatment involves the use of antibiotics, such as flucloxacillin, for 10-14 days. Breastfeeding or expressing milk should continue during treatment to prevent complications such as breast abscess.

Breast engorgement is another common problem that causes breast pain in breastfeeding women. It occurs in the first few days after birth and affects both breasts. Hand expression of milk can help relieve the discomfort of engorgement. Raynaud’s disease of the nipple is a less common problem that causes nipple pain and blanching. Treatment involves minimizing exposure to cold, using heat packs, and avoiding caffeine and smoking.

If a breastfed baby loses more than 10% of their birth weight in the first week of life, it may be a sign of poor weight gain. This should prompt consideration of the above breastfeeding problems and an expert review of feeding. Monitoring of weight should continue until weight gain is satisfactory.

Pregnant women who have a history of VTE should receive LMWH throughout their pregnancy and up to 6 weeks after giving birth to prevent clotting. Warfarin is not recommended during pregnancy due to its teratogenic effects, and LMWH is preferred due to its lower side effect profile and reduced need for monitoring.

Venous Thromboembolism in Pregnancy: Risk Assessment and Prophylactic Measures

Pregnancy increases the risk of developing venous thromboembolism (VTE), a condition that can be life-threatening for both the mother and the fetus. To prevent VTE, it is important to assess a woman’s individual risk during pregnancy and initiate appropriate prophylactic measures. This risk assessment should be done at the first antenatal booking and on any subsequent hospital admission.

Women with a previous history of VTE are automatically considered high risk and require low molecular weight heparin throughout the antenatal period, as well as input from experts. Women at intermediate risk due to hospitalization, surgery, co-morbidities, or thrombophilia should also be considered for antenatal prophylactic low molecular weight heparin.

The risk assessment at booking should include factors that increase the likelihood of developing VTE, such as age over 35, body mass index over 30, parity over 3, smoking, gross varicose veins, current pre-eclampsia, immobility, family history of unprovoked VTE, low-risk thrombophilia, multiple pregnancy, and IVF pregnancy.

If a woman has four or more risk factors, immediate treatment with low molecular weight heparin should be initiated and continued until six weeks postnatal. If a woman has three risk factors, low molecular weight heparin should be initiated from 28 weeks and continued until six weeks postnatal.

If a diagnosis of deep vein thrombosis (DVT) is made shortly before delivery, anticoagulation treatment should be continued for at least three months, as in other patients with provoked DVTs. Low molecular weight heparin is the treatment of choice for VTE prophylaxis in pregnancy, while direct oral anticoagulants (DOACs) and warfarin should be avoided.

In summary, a thorough risk assessment and appropriate prophylactic measures can help prevent VTE in pregnancy, which is crucial for the health and safety of both the mother and the fetus.

Differentiating between types of miscarriage: A case study

A patient presents with vaginal bleeding and cramping at 8 weeks gestation. An ultrasound shows a viable pregnancy with fetal cardiac activity and a gestational sac within the uterus. The cervical os is closed. What type of miscarriage is this?

Threatened miscarriage is the most likely diagnosis in this case. The patient can be reassured with precautions, as over 75% of pregnancies with threatened miscarriage do not abort. However, there is an increased risk of growth restriction and abnormal placentation in the third trimester.

Ectopic pregnancy can be ruled out as the ultrasound has established the gestational sac within the uterus, not within the adnexa. Septic miscarriage is also unlikely as the patient does not demonstrate signs of infection, such as fever, and the cervical os is closed.

A missed miscarriage can be ruled out as fetal cardiac activity was seen on ultrasound. In a complete miscarriage, the uterus would not have a gestational sac.

In conclusion, differentiating between types of miscarriage is important in determining appropriate management and counseling for patients. In this case, a diagnosis of threatened miscarriage allows for reassurance and monitoring of potential complications later in pregnancy.

When a pregnant woman is exposed to chickenpox, the first step is to check if she has varicella antibodies. If she is unsure whether she has had chickenpox in the past, the presence or absence of antibodies will determine the next course of action.

If a pregnant woman is over 20 weeks gestation and does not have varicella antibodies, she should be given varicella-zoster immunoglobulin or oral acyclovir within 7-14 days of exposure. Delaying the administration of oral acyclovir can reduce the risk of developing chickenpox.

Oral acyclovir is also recommended if a pregnant woman over 20 weeks gestation develops chickenpox. However, caution should be exercised if the patient is under 20 weeks gestation and does not have any symptoms of chickenpox.

The varicella-zoster vaccine is not recommended for pregnant women as it is a live attenuated vaccine that can cross the placenta and cause foetal varicella syndrome. It can be given to women who have not had chickenpox and are not immune to antibody testing, but they should avoid getting pregnant for three months after receiving the vaccine.

Varicella-zoster immunoglobulin is recommended for pregnant women who are not immune to varicella on antibody testing and can receive it within 10 days of exposure. However, it provides short-lived protection, so patients should be advised to get the varicella-zoster vaccine after their pregnancy.

Chickenpox exposure in pregnancy can pose risks to both the mother and fetus, including fetal varicella syndrome. Post-exposure prophylaxis (PEP) with varicella-zoster immunoglobulin (VZIG) or antivirals should be given to non-immune pregnant women, with timing dependent on gestational age. If a pregnant woman develops chickenpox, specialist advice should be sought and oral acyclovir may be given if she is ≥ 20 weeks and presents within 24 hours of onset of the rash.